Nathan Jorgensen PhD, MBA brings a comprehensive background of buy-side, sell-side, consulting, and scientific experience to his role at Vor Bio. At QIA, the sovereign wealth fund of the State of Qatar, he spearheaded biotechnology and pharmaceutical investment efforts, which included opportunities in public, private, and specialty investments. Prior to joining QIA, he led investments in therapeutics at Calamos, a growth-focused public equity investment firm with $25 billion of assets under management. Before joining Calamos, Nathan covered mid- and large-cap biotech companies at the investment bank Stifel Nicolaus.
Prior to working on Wall Street, Nathan investigated the pathobiology of Parkinson’s disease at the Columbia University Medical Center as a postdoctoral scientist. He earned an MBA from the Johnson School at Cornell University and a PhD from the University of Minnesota.